Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astri Therapeutics Inc (ATXS)

Astri Therapeutics Inc (ATXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Astri Therapeutics Inc 22 Boston Wharf Road 10th Floor Boston MA 02210 USA

www.astriatx.com Employees: 59 P: 617-349-1971 F: 617-273-2637

Description:

Astria Therapeutics is a biopharmaceutical company which focuses on therapies to treat allergic and immunological diseases. The company's program include STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Astria Therapeutics, formerly known as Catabasis Pharmaceuticals Inc., is based in BOSTON.

Key Statistics

Overview:

Market Capitalization, $K 538,380
Enterprise Value, $K 458,170
Shares Outstanding, K 56,434
Annual Sales, $ 0 K
Annual Net Income, $ -72,890 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -24,530 K
EBIT, $ -100,960 K
EBITDA, $ -100,960 K
60-Month Beta 0.67
% of Insider Shareholders 2.90%
% of Institutional Shareholders 98.98%
Float, K 54,797
% Float 97.10%
Short Volume Ratio 0.79

Growth:

1-Year Return 23.40%
3-Year Return 76.99%
5-Year Return -73.28%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 92.12%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.42 on 11/13/24
Next Earnings Date 11/11/24
Earnings Per Share ttm -2.09
EPS Growth vs. Prev Qtr 2.33%
EPS Growth vs. Prev Year 33.33%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 08/20/21

ATXS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -43.58%
Return-on-Assets % -29.36%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.18
Book Value/Share 4.37
Interest Coverage -1.84
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar